Ligand Operating Income from 2010 to 2024

LGND Stock  USD 80.54  0.10  0.12%   
Ligand Pharmaceuticals' Operating Income is increasing over the years with stable fluctuation. Overall, Operating Income is expected to go to about 10.3 M this year. Operating Income is earnings before interest and taxes (EBIT), representing the amount of profit Ligand Pharmaceuticals Incorporated generates from its operations. View All Fundamentals
 
Operating Income  
First Reported
1994-03-31
Previous Quarter
-3.4 M
Current Value
M
Quarterly Volatility
77.8 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Ligand Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ligand Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 37.4 M, Interest Expense of 623.2 K or Total Revenue of 101.8 M, as well as many indicators such as Price To Sales Ratio of 9.2, Dividend Yield of 0.42 or PTB Ratio of 1.67. Ligand financial statements analysis is a perfect complement when working with Ligand Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Ligand Pharmaceuticals Correlation against competitors.

Latest Ligand Pharmaceuticals' Operating Income Growth Pattern

Below is the plot of the Operating Income of Ligand Pharmaceuticals Incorporated over the last few years. Operating Income is the amount of profit realized from Ligand Pharmaceuticals operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Ligand Pharmaceuticals Incorporated is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Ligand Pharmaceuticals' Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Ligand Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Operating Income10 Years Trend
Pretty Stable
   Operating Income   
       Timeline  

Ligand Operating Income Regression Statistics

Arithmetic Mean26,194,403
Geometric Mean14,711,415
Coefficient Of Variation182.66
Mean Deviation33,458,664
Median10,312,050
Standard Deviation47,847,216
Sample Variance2289.4T
Range189.2M
R-Value0.14
Mean Square Error2415.2T
R-Squared0.02
Significance0.61
Slope1,526,912
Total Sum of Squares32051T

Ligand Operating Income History

202410.3 M
20239.8 M
2022-25.5 M
202178.9 M
20208.6 M
2019-5.7 M
2018163.7 M

Other Fundumenentals of Ligand Pharmaceuticals

Ligand Pharmaceuticals Operating Income component correlations

0.860.090.67-0.230.880.90.87-0.010.61-0.390.82-0.070.370.460.790.620.580.87-0.63-0.18-0.80.870.81-0.53
0.860.110.88-0.310.810.670.660.00.66-0.420.80.340.720.330.680.860.570.8-0.780.23-0.790.680.69-0.8
0.090.110.11-0.150.380.0-0.330.040.66-0.08-0.18-0.150.290.670.60.28-0.67-0.16-0.22-0.14-0.04-0.07-0.35-0.19
0.670.880.11-0.430.660.470.5-0.270.61-0.060.770.510.830.460.520.880.410.71-0.850.37-0.730.590.61-0.87
-0.23-0.31-0.15-0.43-0.12-0.05-0.1-0.14-0.25-0.18-0.180.16-0.3-0.36-0.4-0.23-0.12-0.140.480.150.09-0.15-0.110.43
0.880.810.380.66-0.120.740.64-0.070.72-0.360.68-0.030.560.510.860.70.30.72-0.62-0.18-0.780.750.63-0.54
0.90.670.00.47-0.050.740.92-0.10.49-0.310.78-0.20.090.480.670.420.50.82-0.39-0.31-0.680.940.86-0.39
0.870.66-0.330.5-0.10.640.92-0.130.24-0.250.85-0.130.110.230.480.390.750.89-0.41-0.26-0.720.930.96-0.36
-0.010.00.04-0.27-0.14-0.07-0.1-0.130.08-0.13-0.31-0.21-0.22-0.230.14-0.28-0.01-0.270.36-0.220.37-0.28-0.280.28
0.610.660.660.61-0.250.720.490.240.08-0.190.30.120.460.710.760.55-0.070.31-0.520.1-0.330.430.21-0.53
-0.39-0.42-0.08-0.06-0.18-0.36-0.31-0.25-0.13-0.19-0.19-0.05-0.150.14-0.35-0.37-0.28-0.30.36-0.060.31-0.19-0.210.33
0.820.8-0.180.77-0.180.680.780.85-0.310.3-0.190.250.50.360.480.740.620.98-0.640.04-0.930.850.92-0.66
-0.070.34-0.150.510.16-0.03-0.2-0.13-0.210.12-0.050.250.61-0.16-0.290.540.130.16-0.320.9-0.24-0.130.05-0.49
0.370.720.290.83-0.30.560.090.11-0.220.46-0.150.50.610.230.40.890.150.44-0.760.46-0.620.210.25-0.81
0.460.330.670.46-0.360.510.480.23-0.230.710.140.36-0.160.230.70.42-0.340.35-0.45-0.25-0.370.490.23-0.41
0.790.680.60.52-0.40.860.670.480.140.76-0.350.48-0.290.40.70.570.050.54-0.58-0.4-0.570.630.42-0.52
0.620.860.280.88-0.230.70.420.39-0.280.55-0.370.740.540.890.420.570.260.71-0.860.36-0.830.490.51-0.9
0.580.57-0.670.41-0.120.30.50.75-0.01-0.07-0.280.620.130.15-0.340.050.260.64-0.320.16-0.470.520.72-0.26
0.870.8-0.160.71-0.140.720.820.89-0.270.31-0.30.980.160.440.350.540.710.64-0.64-0.04-0.940.870.93-0.6
-0.63-0.78-0.22-0.850.48-0.62-0.39-0.410.36-0.520.36-0.64-0.32-0.76-0.45-0.58-0.86-0.32-0.64-0.240.71-0.5-0.490.87
-0.180.23-0.140.370.15-0.18-0.31-0.26-0.220.1-0.060.040.90.46-0.25-0.40.360.16-0.04-0.24-0.02-0.29-0.13-0.36
-0.8-0.79-0.04-0.730.09-0.78-0.68-0.720.37-0.330.31-0.93-0.24-0.62-0.37-0.57-0.83-0.47-0.940.71-0.02-0.75-0.780.64
0.870.68-0.070.59-0.150.750.940.93-0.280.43-0.190.85-0.130.210.490.630.490.520.87-0.5-0.29-0.750.94-0.48
0.810.69-0.350.61-0.110.630.860.96-0.280.21-0.210.920.050.250.230.420.510.720.93-0.49-0.13-0.780.94-0.5
-0.53-0.8-0.19-0.870.43-0.54-0.39-0.360.28-0.530.33-0.66-0.49-0.81-0.41-0.52-0.9-0.26-0.60.87-0.360.64-0.48-0.5
Click cells to compare fundamentals

About Ligand Pharmaceuticals Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Ligand Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Ligand Pharmaceuticals investors use historical funamental indicators, such as Ligand Pharmaceuticals's Operating Income, to determine how well the company is positioned to perform in the future. Although Ligand Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Ligand Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Ligand Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Ligand Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Ligand Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Operating Income9.8 M10.3 M
Non Operating Income Net Other-13.8 M-13.1 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Information and Resources on Investing in Ligand Stock

When determining whether Ligand Pharmaceuticals is a strong investment it is important to analyze Ligand Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ligand Pharmaceuticals' future performance. For an informed investment choice regarding Ligand Stock, refer to the following important reports:
Check out the analysis of Ligand Pharmaceuticals Correlation against competitors.
You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ligand Pharmaceuticals. If investors know Ligand will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ligand Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
1.032
Earnings Share
5.35
Revenue Per Share
6.774
Quarterly Revenue Growth
(0.30)
Return On Assets
(0)
The market value of Ligand Pharmaceuticals is measured differently than its book value, which is the value of Ligand that is recorded on the company's balance sheet. Investors also form their own opinion of Ligand Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ligand Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ligand Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ligand Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ligand Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ligand Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ligand Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.